Immune checkpoint inhibitors in renal cell carcinoma

Ross, K. and Jones, R. J. (2017) Immune checkpoint inhibitors in renal cell carcinoma. Clinical Science, 131(21), pp. 2627-2642. (doi: 10.1042/CS20160894) (PMID:29079639)

[img]
Preview
Text
151307.pdf - Published Version
Available under License Creative Commons Attribution.

843kB

Abstract

The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain. Renal cancer was, historically, one of a small number of tumour types where immune manipulation had been shown to be effective. The current generation of immune checkpoint inhibitors are rapidly entering into routine clinical practice in the management of a number of tumour types, including renal cancer, where one drug, nivolumab, an anti-programmed death-1 (PD-1) monoclonal antibody (mAb), is licensed for patients who have progressed on prior systemic treatment. Ongoing trials aim to maximize the benefits that can be gained from this new class of drug by exploring optimal timing in the natural course of the disease as well as combinations with other checkpoint inhibitors and drugs from different classes.

Item Type:Articles (Editorial)
Keywords:Cancer, immunology, immunomodulation.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jones, Professor Robert
Authors: Ross, K., and Jones, R. J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Clinical Science
Publisher:Portland Press
ISSN:0143-5221
ISSN (Online):1470-8736
Published Online:27 October 2017
Copyright Holders:Copyright © 2017 The Authors
First Published:First published in Clinical Science 131(21): 2627-2642
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record